147 related articles for article (PubMed ID: 32014929)
1. Adherence to Adjuvant Aromatase Inhibitor Therapy Among Postmenopausal Hispanic/Latino Women With Breast Cancer.
Philipovskiy A; Campbell A; Heydarian R; Castillo B; Dwivedi AK; McCallum R; Aguilera R; Gaur S; Nahleh Z
Anticancer Res; 2020 Feb; 40(2):857-864. PubMed ID: 32014929
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported Adherence to Adjuvant Aromatase Inhibitor Therapy Using the Morisky Medication Adherence Scale: An Evaluation of Predictors.
Kesmodel SB; Goloubeva OG; Rosenblatt PY; Heiss B; Bellavance EC; Chumsri S; Bao T; Thompson J; Nightingale G; Tait NS; Nichols EM; Feigenberg SJ; Tkaczuk KH
Am J Clin Oncol; 2018 May; 41(5):508-512. PubMed ID: 27322700
[TBL] [Abstract][Full Text] [Related]
3. Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors.
Brier MJ; Chambless DL; Gross R; Chen J; Mao JJ
Cancer; 2017 Jan; 123(1):169-176. PubMed ID: 27570979
[TBL] [Abstract][Full Text] [Related]
4. Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy.
Kimmick G; Edmond SN; Bosworth HB; Peppercorn J; Marcom PK; Blackwell K; Keefe FJ; Shelby RA
Breast; 2015 Oct; 24(5):630-6. PubMed ID: 26189978
[TBL] [Abstract][Full Text] [Related]
5. Adherence to adjuvant endocrine therapy in postmenopausal breast cancer patients: A 5-year prospective study.
Hagen KB; Aas T; Kvaløy JT; Søiland H; Lind R
Breast; 2019 Apr; 44():52-58. PubMed ID: 30641300
[TBL] [Abstract][Full Text] [Related]
6. Identifying socio-demographic and clinical characteristics associated with medication beliefs about aromatase inhibitors among postmenopausal women with breast cancer.
Salgado TM; Davis EJ; Farris KB; Fawaz S; Batra P; Henry NL
Breast Cancer Res Treat; 2017 Jun; 163(2):311-319. PubMed ID: 28251384
[TBL] [Abstract][Full Text] [Related]
7. Sexual problems during the first 2 years of adjuvant treatment with aromatase inhibitors.
Schover LR; Baum GP; Fuson LA; Brewster A; Melhem-Bertrandt A
J Sex Med; 2014 Dec; 11(12):3102-11. PubMed ID: 25141792
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer.
Brett J; Fenlon D; Boulton M; Hulbert-Williams NJ; Walter FM; Donnelly P; Lavery B; Morgan A; Morris C; Watson E
Eur J Cancer Care (Engl); 2018 Jan; 27(1):. PubMed ID: 27901302
[TBL] [Abstract][Full Text] [Related]
9. Association between self-report adherence measures and oestrogen suppression among breast cancer survivors on aromatase inhibitors.
Brier MJ; Chambless D; Gross R; Su HI; DeMichele A; Mao JJ
Eur J Cancer; 2015 Sep; 51(14):1890-6. PubMed ID: 26169018
[TBL] [Abstract][Full Text] [Related]
10. Use of a web-based app to improve breast cancer symptom management and adherence for aromatase inhibitors: a randomized controlled feasibility trial.
Graetz I; McKillop CN; Stepanski E; Vidal GA; Anderson JN; Schwartzberg LS
J Cancer Surviv; 2018 Aug; 12(4):431-440. PubMed ID: 29492753
[TBL] [Abstract][Full Text] [Related]
11. Ageing perceptions and non-adherence to aromatase inhibitors among breast cancer survivors.
Brier MJ; Chambless DL; Chen J; Mao JJ
Eur J Cancer; 2018 Mar; 91():145-152. PubMed ID: 29329697
[TBL] [Abstract][Full Text] [Related]
12. Adherence to Adjuvant Endocrine Therapy in Women With Breast Cancer: A Prospective Observational Study in Japanese Women.
Kuba S; Maeda S; Matsumoto M; Yamanouchi K; Yano H; Morita M; Sakimura C; Hatachi T; Tokai Y; Takatsuki M; Fujioka H; Hayashida N; Nagayasu T; Eguchi S
Clin Breast Cancer; 2018 Apr; 18(2):150-156. PubMed ID: 29290564
[TBL] [Abstract][Full Text] [Related]
13. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
Winer EP; Hudis C; Burstein HJ; Wolff AC; Pritchard KI; Ingle JN; Chlebowski RT; Gelber R; Edge SB; Gralow J; Cobleigh MA; Mamounas EP; Goldstein LJ; Whelan TJ; Powles TJ; Bryant J; Perkins C; Perotti J; Braun S; Langer AS; Browman GP; Somerfield MR
J Clin Oncol; 2005 Jan; 23(3):619-29. PubMed ID: 15545664
[TBL] [Abstract][Full Text] [Related]
14. Excess mortality in postmenopausal high-risk women who only receive adjuvant endocrine therapy for estrogen receptor positive breast cancer.
Ejlertsen B; Jensen MB; Mouridsen HT;
Acta Oncol; 2014 Feb; 53(2):174-85. PubMed ID: 24219541
[TBL] [Abstract][Full Text] [Related]
15. Effect of Aromatase Inhibitor Therapy on Sleep and Activity Patterns in Early-stage Breast Cancer.
Bhave MA; Speth KA; Kidwell KM; Lyden A; Alsamarraie C; Murphy SL; Henry NL
Clin Breast Cancer; 2018 Apr; 18(2):168-174.e2. PubMed ID: 29361424
[TBL] [Abstract][Full Text] [Related]
16. Physical activity and health-related quality of life among postmenopausal women with breast cancer treated with aromatase inhibitors.
Dibble KE; Bellizzi KM; Taxel P; Pescatello LS; Siembida EJ; Schifano ED; Guarneri S; Tannenbaum S
Support Care Cancer; 2021 May; 29(5):2385-2394. PubMed ID: 32918610
[TBL] [Abstract][Full Text] [Related]
17. The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study.
Neven P; Markopoulos C; Tanner M; Marty M; Kreienberg R; Atkins L; Franquet A; Gnant M; Neciosup S; Tesarova P; Barni S; Deschamp V
Breast; 2014 Aug; 23(4):393-9. PubMed ID: 24675394
[TBL] [Abstract][Full Text] [Related]
18. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
[TBL] [Abstract][Full Text] [Related]
19. Identification of tools to measure changes in musculoskeletal symptoms and physical functioning in women with breast cancer receiving aromatase inhibitors.
Swenson KK; Nissen MJ; Henly SJ; Maybon L; Pupkes J; Zwicky K; Tsai ML; Shapiro AC
Oncol Nurs Forum; 2013 Nov; 40(6):549-57. PubMed ID: 24161633
[TBL] [Abstract][Full Text] [Related]
20. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
Lintermans A; Van Asten K; Wildiers H; Laenen A; Paridaens R; Weltens C; Verhaeghe J; Vanderschueren D; Smeets A; Van Limbergen E; Leunen K; Christiaens MR; Neven P
Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
